10699153	183	Kim S	Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases.	Pharmacological reviews	2000	150
14610101	183	Schlaich MP	Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.	Hypertension	2004	80
15149345	183	de Zeeuw D	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.	Kidney international	2004	141
15302780	183	de Zeeuw D	Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.	Circulation	2004	99
16336578	183	Remuzzi G	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.	Kidney international. Supplement	2005	68
17409317	183	Eijkelkamp WB	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.	Journal of the American Society of Nephrology 	2007	57
17494887	183	Kaneshiro Y	Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats.	Journal of the American Society of Nephrology 	2007	59
19075095	183	Kobori H	Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients.	Hypertension	2009	60
19145003	183	Parving HH	Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.	Nephrology, dialysis, transplantation 	2009	51
20234356	183	Briet M	Aldosterone: effects on the kidney and cardiovascular system.	Nature reviews. Nephrology	2010	50
20351344	183	Forman JP	Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans.	Hypertension	2010	53
20442753	183	Kotsis V	Mechanisms of obesity-induced hypertension.	Hypertension research 	2010	67
21734720	183	Fisher JP	The sympathetic nervous system and blood pressure in humans: implications for hypertension.	Journal of human hypertension	2012	35
24981816	183	Wang XH	Mechanisms of muscle wasting in chronic kidney disease.	Nature reviews. Nephrology	2014	28
25092601	183	Alge JL	Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications.	Clinical journal of the American Society of Nephrology 	2015	23
25421983	183	Li W	Intracerebroventricular infusion of the (Pro)renin receptor antagonist PRO20 attenuates deoxycorticosterone acetate-salt-induced hypertension.	Hypertension	2015	19
25767285	183	Hall JE	Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms.	Circulation research	2015	52
21779001	207	Kato H	mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway.	Cell death and differentiation	2012	60
12753285	673	Yamaguchi T	Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.	Kidney international	2003	91
24508103	673	McArthur GA	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.	The Lancet. Oncology	2014	119
24768112	673	Brose MS	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.	Lancet	2014	112
25124676	712	Orbai AM	Anti-C1q antibodies in systemic lupus erythematosus.	Lupus	2015	16
20606628	718	Fakhouri F	C3 glomerulopathy: a new classification.	Nature reviews. Nephrology	2010	60
17420427	920	Silverberg MJ	Older age and the response to and tolerability of antiretroviral therapy.	Archives of internal medicine	2007	56
18190322	920	Goulet JL	Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?	Clinical infectious diseases 	2007	99
24045046	920	Jane-Wit D	Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells.	Circulation	2013	28
20124537	966	Hemmelgarn BR	Relation between kidney function, proteinuria, and adverse outcomes.	JAMA	2010	201
20170948	966	Bakris GL	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.	Lancet	2010	50
22206742	966	Jotwani V	Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors.	American journal of kidney diseases 	2012	31
22733312	966	Bao Y	Frailty, dialysis initiation, and mortality in end-stage renal disease.	Archives of internal medicine	2012	57
23782649	966	Worthley SG	Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.	European heart journal	2013	35
24902920	966	Ambrosius WT	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).	Clinical trials	2014	47
25393378	966	Naik RP	Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.	JAMA	2014	23
26867814	966	Obi Y	Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study.	American journal of kidney diseases 	2016	13
15590763	1351	Foley RN	Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.	Journal of the American Society of Nephrology 	2005	165
24153250	1392	Vanuytsel T	Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism.	Gut	2014	26
11728958	1401	Kalantar-Zadeh K	A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients.	American journal of kidney diseases 	2001	96
16251239	1401	Fried LF	Kidney function as a predictor of noncardiovascular mortality.	Journal of the American Society of Nephrology 	2005	78
20048208	1401	Schnabel RB	Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community.	Circulation	2010	65
20538833	1401	Goicoechea M	Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.	Clinical journal of the American Society of Nephrology 	2010	124
21324198	1401	Koch A	Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.	Critical care	2011	50
24352789	1489	Afshar-Oromieh A	Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.	European journal of nuclear medicine and molecular imaging	2014	32
23341990	1493	Voskens CJ	The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.	PloS one	2013	45
25621841	1493	Shin DS	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?	Current opinion in immunology	2015	63
20981034	1536	Touyz RM	Reactive oxygen species and vascular biology: implications in human hypertension.	Hypertension research 	2011	81
22445098	1536	Montezano AC	Molecular mechanisms of hypertension--reactive oxygen species and antioxidants: a basic science update for the clinician.	The Canadian journal of cardiology	2012	43
22713144	1536	Montezano AC	Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies.	Annals of medicine	2012	41
23600794	1536	Montezano AC	Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research.	Antioxidants and redox signaling	2014	29
16176115	1544	Anderson GD	Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.	Clinical pharmacokinetics	2005	130
23132334	1544	Reese MJ	In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.	Drug metabolism and disposition	2013	35
16581329	1576	Law M	Statin safety: a systematic review.	The American journal of cardiology	2006	97
23584425	1579	Wu CC	20-HETE and blood pressure regulation: clinical implications.	Cardiology in review	2014	29
23774812	1585	Brown NJ	Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.	Nature reviews. Nephrology	2013	30
17368179	1594	Hewison M	Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease.	The Journal of steroid biochemistry and molecular biology	2007	89
21845364	1594	White JH	Vitamin D metabolism and signaling in the immune system.	Reviews in endocrine and metabolic disorders	2012	39
10969042	1636	Donoghue M	A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.	Circulation research	2000	242
16338452	1636	Casas JP	Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.	Lancet	2005	78
17035613	1636	Rüster C	Renin-angiotensin-aldosterone system and progression of renal disease.	Journal of the American Society of Nephrology 	2006	67
17970613	1636	Atlas SA	The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.	Journal of managed care pharmacy 	2007	67
17984482	1636	Kunz R	Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.	Annals of internal medicine	2008	94
19846849	1636	ESCAPE Trial Group.	Strict blood-pressure control and progression of renal failure in children.	The New England journal of medicine	2009	100
19926893	1636	Mehdi UF	Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.	Journal of the American Society of Nephrology 	2009	69
20440277	1636	Ruggenenti P	The RAAS in the pathogenesis and treatment of diabetic nephropathy.	Nature reviews. Nephrology	2010	43
23100218	1636	Ruggenenti P	Mechanisms and treatment of CKD.	Journal of the American Society of Nephrology 	2012	34
24206457	1636	Fried LF	Combined angiotensin inhibition for the treatment of diabetic nephropathy.	The New England journal of medicine	2013	107
25399731	1636	Torres VE	Angiotensin blockade in late autosomal dominant polycystic kidney disease.	The New England journal of medicine	2014	25
26268910	1636	de Zeeuw D	The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.	The lancet. Diabetes and endocrinology	2015	21
23932846	1803	Aroor AR	Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.	Metabolism	2013	41
24026560	1803	Groop PH	Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.	Diabetes care	2013	44
26956245	1906	Davenport AP	Endothelin.	Pharmacological reviews	2016	22
24722445	1956	de Zeeuw D	The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.	Journal of the American Society of Nephrology 	2014	36
24970885	1956	Navarro-González JF	Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.	Journal of the American Society of Nephrology 	2015	18
25573908	1956	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	22
27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
17656472	2056	Foley RN	End-stage renal disease in the United States: an update from the United States Renal Data System.	Journal of the American Society of Nephrology 	2007	88
21115615	2056	Bernhardt WM	Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.	Journal of the American Society of Nephrology 	2010	65
18094680	2168	Portilla D	Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery.	Kidney international	2008	80
23689653	2168	McCullough PA	Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference.	Contributions to nephrology	2013	33
17426693	2247	Jiang W	In vitro derivation of functional insulin-producing cells from human embryonic stem cells.	Cell research	2007	86
21126355	2335	Szarka A	Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array.	BMC immunology	2010	86
23687622	2335	Dannenmann SR	Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma.	Oncoimmunology	2013	34
18653228	2475	Motzer RJ	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.	Lancet	2008	647
23312829	2475	Bissler JJ	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.	Lancet	2013	119
24556040	2475	Motzer RJ	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	48
26067126	2475	Curatolo P	Neurological and neuropsychiatric aspects of tuberous sclerosis complex.	The Lancet. Neurology	2015	29
26482279	2475	Motzer RJ	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.	The Lancet. Oncology	2015	57
27279544	2475	Choueiri TK	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2016	35
24661442	2908	Yehuda R	Lower methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of veterans with posttraumatic stress disorder.	Biological psychiatry	2015	41
16299065	3075	Abrera-Abeleda MA	Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease).	Journal of medical genetics	2006	64
18081690	3075	de Córdoba SR	Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H.	Clinical and experimental immunology	2008	75
20513133	3075	Maga TK	Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome.	Human mutation	2010	54
20595690	3075	Noris M	Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.	Clinical journal of the American Society of Nephrology 	2010	127
22456601	3075	Servais A	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.	Kidney international	2012	69
22673887	3075	Sethi S	C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.	Kidney international	2012	45
23307876	3075	Fremeaux-Bacchi V	Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.	Clinical journal of the American Society of Nephrology 	2013	72
23431077	3075	Bresin E	Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.	Journal of the American Society of Nephrology 	2013	46
9884342	3162	Yachie A	Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency.	The Journal of clinical investigation	1999	246
12130498	3162	Jeney V	Pro-oxidant and cytotoxic effects of circulating heme.	Blood	2002	116
23248063	3347	Esler MD	Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.	Circulation	2012	65
18927310	3458	Finke JH	Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.	Clinical cancer research 	2008	113
19487422	3458	Strowig T	Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.	The Journal of experimental medicine	2009	92
25210141	3458	Jensen KJ	Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-controlled trial.	The Journal of infectious diseases	2015	19
26405286	3458	Getahun H	Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.	The European respiratory journal	2015	21
25453823	3553	Chittezhath M	Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression.	Immunity	2014	26
22737606	3558	Galluzzi L	Trial Watch: Adoptive cell transfer immunotherapy.	Oncoimmunology	2012	44
9389420	3569	Pickup JC	NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.	Diabetologia	1997	150
15886319	3569	Kemna E	Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS.	Blood	2005	105
20032961	3569	Murugan R	Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival.	Kidney international	2010	66
24076269	3569	Yao X	Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.	Pharmacology and therapeutics	2014	59
24728071	3569	Miller CJ	Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.	PloS one	2014	22
25388133	3569	Haake DA	Leptospirosis in humans.	Current topics in microbiology and immunology	2015	35
26858430	3569	Morris CJ	Circadian misalignment increases cardiovascular disease risk factors in humans.	Proceedings of the National Academy of Sciences of the United States of America	2016	16
10550418	3630	Meyer TW	Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria.	Diabetologia	1999	104
20171982	3630	Lambert GW	Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications.	Pharmacology and therapeutics	2010	72
16528543	3934	Mishra J	Kidney NGAL is a novel early marker of acute injury following transplantation.	Pediatric nephrology	2006	73
25311702	3934	Liu KD	Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.	American journal of kidney diseases 	2015	18
23883674	3952	Mark AL	Selective leptin resistance revisited.	American journal of physiology. Regulatory, integrative and comparative physiology	2013	35
23564710	4051	Jones G	Cytochrome P450-mediated metabolism of vitamin D.	Journal of lipid research	2014	30
23023777	4353	Lionaki S	Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.	Arthritis and rheumatism	2012	32
10430945	4758	Neumann G	Generation of influenza A viruses entirely from cloned cDNAs.	Proceedings of the National Academy of Sciences of the United States of America	1999	465
12225726	4879	Redfield MM	Plasma brain natriuretic peptide concentration: impact of age and gender.	Journal of the American College of Cardiology	2002	105
18154959	4879	Daniels LB	Natriuretic peptides.	Journal of the American College of Cardiology	2007	127
19329178	4879	Teerlink JR	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.	Lancet	2009	70
20447528	4879	Maisel A	Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.	Journal of the American College of Cardiology	2010	45
19165178	5310	Rossetti S	Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease.	Kidney international	2009	76
20348094	5443	Hall JE	Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins.	The Journal of biological chemistry	2010	118
15814832	5741	Slinin Y	Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.	Journal of the American Society of Nephrology 	2005	76
16316359	5741	Agarwal R	Antiproteinuric effect of oral paricalcitol in chronic kidney disease.	Kidney international	2005	84
2195340	5972	Levine B	Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.	The New England journal of medicine	1990	235
18256393	5972	Gaede P	Effect of a multifactorial intervention on mortality in type 2 diabetes.	The New England journal of medicine	2008	502
18525041	5972	Parving HH	Aliskiren combined with losartan in type 2 diabetes and nephropathy.	The New England journal of medicine	2008	178
19005010	5972	Moranne O	Timing of onset of CKD-related metabolic complications.	Journal of the American Society of Nephrology 	2009	70
22945249	5972	Damasceno A	The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries.	Archives of internal medicine	2012	61
23121378	5972	Parving HH	Cardiorenal end points in a trial of aliskiren for type 2 diabetes.	The New England journal of medicine	2012	133
23349312	5972	Savige J	Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy.	Journal of the American Society of Nephrology 	2013	28
23358488	5972	Makani H	Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.	BMJ	2013	26
24334175	5972	Cherney DZ	Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.	Circulation	2014	105
24343093	5972	Hsu TW	Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.	JAMA internal medicine	2014	28
24694989	5972	Coppo R	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.	Kidney international	2014	35
25349246	5972	Ding Y	Autophagy in diabetic nephropathy.	The Journal of endocrinology	2015	23
25595565	5972	Goicoechea M	Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.	American journal of kidney diseases 	2015	31
21955459	6523	DeFronzo RA	The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.	Diabetes, obesity and metabolism	2012	76
20609968	6524	Bailey CJ	Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.	Lancet	2010	134
24673844	6524	De Nicola L	Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.	American journal of kidney diseases 	2014	23
25271207	6524	Henry RR	Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.	Diabetes care	2015	31
25341005	6524	Vallon V	The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.	Annual review of medicine	2015	18
26620248	6524	Weber MA	Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.	The lancet. Diabetes and endocrinology	2016	15
10028970	7040	Hojo M	Cyclosporine induces cancer progression by a cell-autonomous mechanism.	Nature	1999	115
15231748	7040	Colland F	Functional proteomics mapping of a human signaling pathway.	Genome research	2004	79
22335797	7040	Vallon V	Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.	Annual review of physiology	2012	46
26335400	7040	Richter K	Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences.	Redox biology	2015	18
12124351	7422	Bates DO	VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.	Cancer research	2002	143
18452647	7422	Shibuya M	Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.	BMB reports	2008	52
8395349	7490	Kreidberg JA	WT-1 is required for early kidney development.	Cell	1993	299
10101119	7490	Moore AW	YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis.	Development	1999	102
17699549	8074	Perwad F	Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.	American journal of physiology. Renal physiology	2007	66
22492635	8074	Lim K	Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.	Circulation	2012	99
22703926	8074	Ix JH	Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).	Journal of the American College of Cardiology	2012	82
23505057	8074	Wolf M	Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.	Journal of bone and mineral research 	2013	44
25967123	8074	Isakova T	Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.	Journal of the American Society of Nephrology 	2015	17
25971439	8074	Chonchol M	Low Vitamin D and High Fibroblast Growth Factor 23 Serum Levels Associate with Infectious and Cardiac Deaths in the HEMO Study.	Journal of the American Society of Nephrology 	2016	13
12045255	10159	Nguyen G	Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.	The Journal of clinical investigation	2002	256
17082479	10159	Schefe JH	A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein.	Circulation research	2006	60
12441925	10178	Frank I	An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.	The Journal of urology	2002	122
21902819	11093	Loirat C	Atypical hemolytic uremic syndrome.	Orphanet journal of rare diseases	2011	94
21334736	23523	Budde K	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.	Lancet	2011	43
24357673	26762	Coca SG	Urinary biomarkers of AKI and mortality 3 years after cardiac surgery.	Journal of the American Society of Nephrology 	2014	28
16482562	29126	Blank C	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.	International journal of cancer	2006	75
22658128	29126	Brahmer JR	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.	The New England journal of medicine	2012	1346
25428503	29126	Powles T	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.	Nature	2014	345
26942067	29126	Berghoff AS	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.	Oncoimmunology	2016	14
22535897	57379	Wang R	Physiological implications of hydrogen sulfide: a whiff exploration that blossomed.	Physiological reviews	2012	239
19576682	58492	van Rhijn BW	Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.	European urology	2009	85
17396113	90678	Akcan-Arikan A	Modified RIFLE criteria in critically ill children with acute kidney injury.	Kidney international	2007	160
12024214	116085	Enomoto A	Molecular identification of a renal urate anion exchanger that regulates blood urate levels.	Nature	2002	176
